NCT04580160已完成不适用
Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 162
- 试验地点
- 58
- 主要终点
- Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days
研究概览
简要总结
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or non-pregnant, non-breastfeeding females ≥18 years of age at the time of consent
- •Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures
- •Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to treatment and must use some form of contraception (abstinence is acceptable) throughout the time of clinical trial exit
- •Willing and capable of complying with all required follow-up visits
- •Estimated life expectancy ≥1 year
- •Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable)
- •Body mass index (BMI) <40
- •Clinically significant symptomatic venous outflow obstruction in one iliofemoral venous segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least one of the following clinical indicators:
- •Clinical-Etiology-Anatomy-Pathophysiology (CEAP) score ≥3
- •Venous Clinical Severity Score (VCSS) pain score ≥2
- •Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a DUO Stent
- •Subject is willing and able to comply with PI recommendation for compression therapy, if required
- •Presence of unilateral, non-malignant venous obstruction of the common femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the deep femoral (or profunda) or the lesser trochanter, whichever is most cranial
- •Obstructive lesion(s) able to be treated with continuous stent coverage
- •Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral vein and a landing zone in the CFV free from significant disease requiring treatment
- •Reference vessel diameter is of adequate size to accommodate the appropriate size stent as measured by IVUS
- •All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, depending on the stent size used
- •Ability to cross interventional devices through target lesion(s)
- •In DVT subjects, successful treatment of acute thrombus must have occurred prior to receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute thrombus is defined as reestablishment of antegrade flow with ≤30% residual thrombus (confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure.
- •All subjects must undergo a SARS-CoV-2 test and have a negative test result within 8 days of the index procedure. If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a delay in test results, the subject must complete the COVID-19 questionnaire and must have answered NO to all questions to be eligible for enrollment. A SARS-CoV-2 test will not be required for enrollment if a subject has received a complete cycle of an authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 antibody test and is asymptomatic and has no long-lasting effects (per PI discretion) from a prior COVID-19 infection.
- •A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no history of fever or feeling feverish within 14 days of the index procedure
- •No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positive test, or COVID-19 symptoms
排除标准
- •Target limb symptoms caused by peripheral arterial disease
- •Presence of unresolved significant pulmonary embolism prior to use of the DUO Venous Stent System confirmed by chest CT. If subject has documented history of significant pulmonary embolism within the last 6 months, a chest CT is required to confirm significant pulmonary embolism is not currently present.
- •Presence of IVC obstruction or target venous obstruction that extends into the IVC
- •Presence of acute DVT located outside target limb
- •Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment ≤390 days after the index procedure
- •Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis
- •Coagulopathy causing INR >2 which is not amenable to medical treatment
- •Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood cell (WBC) <3,000 cells/mm3 or >12,500 cells/mm3
- •Uncorrected hemoglobin of ≤9 g/dL
- •Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 mL/min. In subjects with diabetes mellitus, eGFR <45 mL/min.
- •History of Heparin Induced Thrombocytopenia
- •Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or Antithrombin deficiency
- •Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, or titanium
- •Contrast agent allergy that cannot be managed adequately with pre-medication
- •Intended concurrent adjuvant procedure (except for venoplasty) such as creation of temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or saphenous vein stripping during the index procedure
- •Subjects who have had any prior surgical or endovascular procedures to the target vessel. Note that subjects who have had successful catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 90 days prior to the index procedure may be included
- •Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure
- •Planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) 30 days prior to or 30 days after the index procedure
- •Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend into the IVC
- •Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent implants
- •Lesions with intended treatment lengths extending into the IVC
- •No safe landing zone at or above the profunda femoral confluence
- •Participating in another investigational study in which the subject has not completed the primary endpoint(s)
- •Has other comorbidities that, in the opinion of the Investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments
结局指标
主要结局
Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days
时间窗: 30 days
Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including: * Device or procedure-related death * Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units * Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention * Major amputation of the target limb * Clinically significant pulmonary embolism (PE), confirmed by CT angiography * Stent embolization outside of the target vessel * Presence of new thrombus within the stented segment requiring surgical or endovascular intervention
Efficacy - Number of Participants With Primary Patency of Stented Segment at 12 Months
时间窗: 12 months
Primary patency of stented segment at 12 months defined as freedom from: * Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis \>50% within the stented segment. If DUS shows \>50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required. * CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated \>50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS
次要结局
- VCSS Pain Score and Changes in VCSS From Baseline in ITT Patients(12 months)
- Number of ITT Subjects With Primary Assisted Patency at 12 Months(12 months)
- Number of ITT Subjects With Secondary Patency at 12 Months(12 months)
研究者
研究点 (58)
Loading locations...
相似试验
已完成
不适用
Evaluation of the Zilver® Vena™ Venous StentIliofemoral Venous Outflow ObstructionNCT01663051Cook Group Incorporated35
已完成
不适用
VIVO Clinical StudySymptomatic Venous Outflow Obstruction in the Iliofemoral VeinNCT01970007Cook Research Incorporated243
已完成
不适用
Treatment of Vein Stenosis or Occlusion With the Oblique StentIliac Vein StenosisIliac Vein OcclusionNCT05324787Hangzhou Endonom Medtech Co., Ltd.112
尚未招募
早期 1 期
Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA)OsteoarthritisNCT05515523Wake Forest University Health Sciences10
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701